HARBIN, China, Jan. 15 China Sky OneMedical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), aleading fully integrated pharmaceutical company developing and producingover-the-counter drugs in the People's Republic of China ("PRC"), todayannounced that the Company has relocated its headquarters to its new buildingsin the Harbin Song Bei New Development district to better accommodate theCompany's significant growth.
China Sky One Medical completed this first phase of construction inDecember 2009. The Company's two new six-story buildings cost approximately$13 million and will accommodate administration, research and development,accounting, and sales functions. Management believes that combining itsoperations into one centralized location will result in greater efficiency andmake it easier to conduct business.
The Company's new address is No. 2158, North Xiang An Road, Song BeiDistrict, Harbin, Heilongjiang Province, P. R. of China 150028. The maincontact number at the Company is 86-451-8703-2617.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.The Company engages in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic products. Through its wholly-ownedsubsidiaries, Harbin Tian Di Ren Medical Science and Technology Company("TDR"), Harbin First Bio- Engineering Company Limited ("First"), HeilongjiangTianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin ChuangPharmaceutical Company ("Jin Chuang") the Company manufactures and distributesover-the-counter pharmaceutical products, which make up its major revenuesource. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constituteforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements can be identified by the useof forward- looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology. Such statements typically involve risks anduncertainties and may include expectations of future growth or informationregarding the move to new headquarters. Actual results could differ materiallyfrom the expectations reflected in such forward-looking statements as a resultof a variety of factors, including the risks associated with the effect ofchanging economic conditions in The People's Republic of China, variations incash flow, reliance on collaborative retail partners and on new productdevelopment, variations in new product development, risks associated withrapid technological change, and the potential of introduced or undetectedflaws and defects in products, and other risk factors detailed in reportsfiled with the Securities and Exchange Commission from time to time.For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Stanley Hao, CFO Tel: +86-0451-8703-2617 Email: [email protected]
Investor Relations Contact: CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: [email protected]
Web: http://www.ccgirasia.com Mr. R. Micchelli, Sr. Financial Writer Tel: +1-646-454-4516 Email: [email protected]
SOURCE China Sky One Medical, Inc.